LYMPHOMA COALITION
is a worldwide network of patient organisations with a full or partials focus on providing support to those affected by lymphoma, including chronic lymphocytic leukemia.
Find a Member Organisation Near You
Learn more about the findings from the 2024 Global Patient Survey (GPS) on Lymphoma & CLL
View ReportSearch The Resource Library
Browse information on lymphoma diagnosis, treatment & survivorship
🌟 Live from the Friday Satellite Symposia on Haematology, produced by MedscapeLIVE!
Lorna Warwick, Chief Executive Officer of Lymphoma Coalition, is joining the expert panel for “Personalising Relapsed/Refractory DLBCL with Bispecific Antibody Therapy: A Case-Based Discussion.”
This session offers an interactive look at real-world scenarios in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), where clinicians and a patient advocate work through case studies to demonstrate how bispecific antibodies are shaping personalised treatment approaches. The program is designed to support clinical decision-making, highlight emerging practices, and keep attendees current on advancements in care.
Lorna’s participation brings forward real-world patient perspectives and reinforces the importance of integrating patient-centred approaches in advancing diffuse large B-cell lymphoma (DLBCL) care. The session highlights the continued importance of integrating patient perspectives to drive progress in lymphoma treatment.
Lymphoma Coalition is proud to participate in this program and bring the patient perspective to the conversation. ... See MoreSee Less
🌟 Happening now at the Friday Satellite Symposia on Haematology, produced by MedscapeLIVE!
Natacha Bolaños, Head of Membership & Alliances at Lymphoma Coalition, is taking part in “Tailoring Bispecific Antibodies to Individualise R/R Follicular Lymphoma: A Case-Based Discussion.”
This highly interactive session brings together leading clinicians and a patient advocate to walk through real-world cases shaped by audience input. The discussion looks at how bispecific antibodies are being used in relapsed/refractory follicular lymphoma (R/R FL), with a focus on selecting appropriate treatments, managing side effects, and navigating practical challenges patients often face.
Natacha’s contribution centers on treatment decision-making, management of side effects, and addressing access challenges for individuals living with follicular lymphoma (FL).
Lymphoma Coalition is proud to participate in this session and bring the patient perspective to the discussion.
#lymsm #ASH25 ... See MoreSee Less
🌟 Lymphoma Coalition is looking forward to participating in the 67th ASH Annual Meeting and Exposition, taking place 6–9 December 2025 in Orlando, Florida!
This year’s participation highlights LC's continued commitment to amplifying the patient voice through both research and educational engagement.
We’re proud to share that two abstracts based on findings from the Lymphoma Coalition 2024 Global Patient Survey on Lymphomas and CLL have been selected for poster presentation:
🟩 Variances in patient-reported experiences with shared decision-making by biological sex in patients with DLBCL – presented by Lorna Warwick, Chief Executive Officer, Lymphoma Coalition.
🟩 Evolving patient-reported value of treatment attributes in follicular lymphoma: Insights from the Lymphoma Coalition 2024 Global Patient Survey – presented by Natacha Bolaños, Head of Membership & Alliances, Lymphoma Coalition.
Both posters will be presented on Saturday, 6 December 2025, from 5:30 PM to 7:30 PM (ET) at the Orange County Convention Center, West Halls B3–B4.
#ASH25 #lymsm ... See MoreSee Less
Lymphoma Coalition is pleased to announce the appointment of three new members to its Board of Directors: Dr. Clara Chamba (Blood Cancer Foundation of Tanzania-BCFT), Pete DeNardis (International Waldenstrom's Macroglobulinemia Foundation), and Meghan Gutierrez (Lymphoma Research Foundation ).
These leaders join the Board at a pivotal time, bringing essential expertise in policy, diagnostics, research, and patient empowerment that supports LC’s strategic priorities to deliver usable evidence, influence global policy, and ensure equitable care worldwide.
LC is proud to welcome these exceptional leaders and looks forward to the impact their experience will bring to our global community.
Read the full announcement:
🔗 lymphomacoalition.org/lymphoma-coalition-announces-three-new-board-directors-to-drive-2025-2030-s... ... See MoreSee Less
Global Summit 2025 - Amsterdam, 5-7 October - Highlights ... See MoreSee Less
Patient Educational Forum - November 2025 ... See MoreSee Less